Akèy › Maladi Greff-versus-host › Massachusetts
Etid klinik pou Maladi Greff-versus-host nan Massachusetts
10 etid pou Maladi Greff-versus-host ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06910969Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 2 ak plis · Tout sèks · Mizajou Jul 23, 2026 · NCT06991361A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou Jun 16, 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT06615050Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
- Boston Children's Hospital, Boston
Ap rekriteFaz 2
Laj 2 ak plis · Tout sèks · Mizajou May 11, 2026 · NCT04380740Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Mar 11, 2026 · NCT05236062A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 15, 2025 · NCT06619561Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
- Dana Farber, Boston
Ap rekriteEtid obsèvasyon
36 Months · Tout sèks · Mizajou Oct 20, 2025 · NCT05866302IS-free Treg HaploHCT
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Oct 20, 2025 · NCT04678401Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2025 · NCT06462365Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.